tradingkey.logo
搜索

Harvard Bioscience Inc

HBIO
添加自选
6.050USD
-0.100-1.63%
收盘 07/01, 16:00美东报价延迟15分钟
27.29M总市值
亏损市盈率 TTM

Harvard Bioscience Inc

6.050
-0.100-1.63%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-1.63%

5天

-0.49%

1月

-5.47%

6月

-9.54%

今年开始到现在

-9.54%

1年

+1249.24%

关键数据
6.150今开
6.280最高
20.43K成交量
亏损市盈率 TTM
12.69市盈率动
--股息TTM
0.45%换手率
6.150昨收
5.990最低
97.86K成交额
亏损市盈率静
2.72市净率
0.00%股息率 TTM
-12.41%ROA
9.45852周最高
1.51量比
-12.40M净利润
4.51M总股本
-2.1224每股收益TTM
1.55Beta
-78.65%ROE
3.10152周最低
4.72%振幅
55.04%毛利率
27.29M总市值
-0.90回报/风险
5.31%风险率

TradingKey Harvard Bioscience Inc股票评分

单位: USD 更新时间: 2026-06-30

操作建议

Harvard Bioscience Inc当前公司基本面数据相对稳定,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名107/204位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价6.00。中期看,股价处于上升通道。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Harvard Bioscience Inc评分

相关信息

行业排名
107 / 204
全市场排名
250 / 4569
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
看好

Harvard Bioscience Inc亮点

亮点风险
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
业绩增长期
公司处于发展阶段,最新年度总收入86.55M美元
利润高增长
公司净利润处于行业前列,最新年度总收入86.55M美元
估值合理
公司最新PE估值-2.90,处于3年历史合理位
机构减仓
最新机构持股2.44M股,环比减少15.49%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓,最新持仓市值0.00

分析师目标

根据 2 位分析师
买入
评级
6.000
目标均价
-2.44%
涨幅空间

Harvard Bioscience Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Harvard Bioscience Inc简介

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
公司代码HBIO
公司Harvard Bioscience Inc
CEODuke (John D)
网址https://www.harvardbioscience.com/

常见问题

Harvard Bioscience Inc(HBIO)的当前股价是多少?

Harvard Bioscience Inc(HBIO)的当前股价是 6.05。

Harvard Bioscience Inc的股票代码是什么?

Harvard Bioscience Inc的股票代码是HBIO。

Harvard Bioscience Inc股票的52周最高点是多少?

Harvard Bioscience Inc股票的52周最高点是9.46。

Harvard Bioscience Inc股票的52周最低点是多少?

Harvard Bioscience Inc股票的52周最低点是3.10。

Harvard Bioscience Inc的市值是多少?

Harvard Bioscience Inc的市值是27.29M。

现在Harvard Bioscience Inc(HBIO)的股票是买入、持有还是卖出?

根据分析师评级,Harvard Bioscience Inc(HBIO)的总体评级为买入,目标价格为6.00。

Harvard Bioscience Inc(HBIO)股票的每股收益(EPS TTM)是多少

Harvard Bioscience Inc(HBIO)股票的每股收益(EPS TTM)是-12.77。